Tailwinds' Take: the Company is guiding towards a run rate of $144M in adjusted EBITDA by this time next year. With an 8X multiple, $650M in debt and ~78M shares outstanding, Fusion could be at $6.40 per share by...
Tailwinds' Take: The stock has held in despite the shoe not being exercised at all. There is a slew of catalysts coming soon and the trading volume demonstrates that there are eyeballs on this stock. This one should work...
Tailwinds' Take: with the launch of their marquee HOLA project, the Company has said they expect a big ramp in new business. This could be a sign that we're seeing this execution happening. BROOKLYN, N.Y.-- SG Blocks, Inc. (NASDAQ: SGBX), a leading...
Tailwinds' Take: been looking for this deal to happen for a while. Now is the time to start picking away at this. However, while we like the new management and direction, we need to see the company prove the...
Tailwinds' Take: very important press release. Not only did they need capital to grow, but this shows they are delivering on their promises. Perhaps the even more important information, however, is contained in the subtitle, "product innovations to broaden...
I had a follow-up call with Dr. Kumar, CEO of ITUS, today. Basically, I was looking to understand more about the benign versus cancerous tumor diagnosing being performed by ITUS. We covered this and a few other points. Here...
Tailwinds' Take: ITUS has a potentially game-changing diagnostic here. Dr. Kumar's comments about benign studies are quite foreshadowing. We can expect to hear more about this in the future. Also note the multi-billion valuations on liquid biopsy diagnostic companies;...
Tailwinds' Take: while the CrossLayer business launches, the Benchmark side of FTE continues to win contracts fast enough to replace the $300+ million in revenue expected to be generated during 2018. NAPLES, Fla., June 12, 2018 -- FTE Networks, Inc. (NYSE...
Tailwinds' Take: Time is running out on this Rights Offering. With the money only accepted on Nasdaq listing, with business picking up at MoneyOnMobile, and with a very low valuation, this is a good entry point. DALLAS and MUMBAI, India, June 12, 2018 /PRNewswire/...
Tailwinds' Take: Scientists of this caliber don't join SABs unless there's something exciting going on. We eagerly anticipate the release of Non-Human Primate data sometime (hopefully) soon. RICHMOND, British Columbia &  GUILFORD, Conn.–(Business Wire)– Bioasis Technologies, Inc . (TSX.V:BTI; OTCQB:BIOAF), a biopharmaceutical company...